Consolidation and Competition in the Pharmaceutical Industry
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
- Rebecca Henderson & Iain Cockburn, 1996.
"Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery,"
RAND Journal of Economics, The RAND Corporation, vol. 27(1), pages 32-59, Spring.
- Rebecca Henderson & Iain Cockburn, "undated". "Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery," Working Papers ec25/94, Department of Economics, University of Lancaster.
- F. M. Scherer & Dietmar Harhoff & J, rg Kukies, 2000. "Uncertainty and the size distribution of rewards from innovation," Journal of Evolutionary Economics, Springer, vol. 10(1), pages 175-200.
- Hannah Kettler, 1999. "Updating the Cost of a New Chemical Entity," Monograph 000456, Office of Health Economics.
- Grabowski, Henry & Mullins, C. Daniel, 1997. "Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions," Social Science & Medicine, Elsevier, vol. 45(4), pages 535-544, August.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
- Billette de Villemeur, Etienne & Scannell, Jack & Versaevel, Bruno, 2021.
"Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?,"
MPRA Paper
108233, University Library of Munich, Germany.
- Jack Scannell & Bruno Versaevel & Etienne Billette de Villemeur, 2022. "Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?," Post-Print hal-03967759, HAL.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Albert N. Link & John T. Scott, 2018.
"Propensity to Patent and Firm Size for Small R&D-Intensive Firms,"
Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 52(4), pages 561-587, June.
- Link, Albert & Scott, John, 2018. "Propensity to Patent and Firm Size for Small R&D-Intensive Firms," UNCG Economics Working Papers 18-1, University of North Carolina at Greensboro, Department of Economics.
- Steven Casper;Hannah Kettler, 2000. "The Road to Sustainability in the UK and German Biotechnology Industries," Monograph 000466, Office of Health Economics.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005.
"Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances,"
Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
- Patricia M. Danzon & Sean Nicholson & Nuno Sousa Pereira, 2003. "Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances," NBER Working Papers 9615, National Bureau of Economic Research, Inc.
- Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
- Tannista Banerjee & Ralph Siebert, 2013.
"The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry,"
Auburn Economics Working Paper Series
auwp2013-20, Department of Economics, Auburn University.
- Tannista Banerjee & Ralph Siebert, 2014. "The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry," CESifo Working Paper Series 4567, CESifo.
- Banerjee, Tannista & Siebert, Ralph, 2017. "Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry," Research Policy, Elsevier, vol. 46(7), pages 1255-1271.
- Hannah Kettler, 2000. "Narrowing the Gap between provision and need for medicines in developing countries," Monograph 000461, Office of Health Economics.
- Catherine Matraves, 1998. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," CIG Working Papers FS IV 98-17, Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG).
- Tannistra Banerjee & Stephen Martin, 2015.
"Pharmaceutical Regulation and Innovative Performance: A Decision‐theoretic Model,"
Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 36(3), pages 177-190, April.
- Tannista Banerjee & Stephen Martin, 2013. "Pharmaceutical regulation and innovative performance: a decision-theoretic model," Auburn Economics Working Paper Series auwp2013-21, Department of Economics, Auburn University.
- Tannista Banerjee & Ralph Siebert, 2017. "The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market," Southern Economic Journal, John Wiley & Sons, vol. 84(1), pages 202-228, July.
- Bertoni, Fabio & Tykvová, Tereza, 2012. "Which form of venture capital is most supportive of innovation?," ZEW Discussion Papers 12-018, ZEW - Leibniz Centre for European Economic Research.
- Jörg Mahlich & Thomas Roediger-Schluga, 2006.
"The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan,"
Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 145-164, March.
- Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," MERIT Working Papers 2006-015, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Steven Casper & Catherine Matraves, 1997. "Corporate Governance and Firm Strategy in the Pharmaceutical Industry," CIG Working Papers FS IV 97-20, Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG).
- Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
- Mary K. Olson, 2000. "Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 9(3), pages 363-395, June.
- de Rassenfosse, Gaétan, 2013.
"Do firms face a trade-off between the quantity and the quality of their inventions?,"
Research Policy, Elsevier, vol. 42(5), pages 1072-1079.
- Gaétan de Rassenfosse, 2013. "Do Firms Face a Trade-Off between the Quantity and the Quality of Their Inventions?," Melbourne Institute Working Paper Series wp2013n06, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
- Zhang, Feng & Jiang, Guohua & Cantwell, John A., 2015. "Subsidiary exploration and the innovative performance of large multinational corporations," International Business Review, Elsevier, vol. 24(2), pages 224-234.
More about this item
Keywords
Consolidation and Competition in the Pharmaceutical Industry;JEL classification:
- I1 - Health, Education, and Welfare - - Health
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:monogr:000468. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.